Electrophysiological Registry Duesseldorf

NCT07196176 | Recruiting

• 1 other identifier: EPS Registry
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

This registry at University Hospital Düsseldorf collects retrospective and prospective (from 2019 onward) data on patients undergoing electrophysiological studies (EPS), catheter ablation, and electrical cardioversion. The primary goal is to evaluate safety, efficacy, and clinical outcomes of these standard procedures in routine care. Data will be used for quality assurance and to identify prognostic patient- and procedure-related factors.

Conditions

Atrial Fibrillation (AF); Atrial Flutter; Supraventricular Tachycardias; Ventricular Tachycardia (VT)

Keywords

atrial fibrillation; catheter ablation; cardioversion

Outcome Measures

Primary Outcomes (2)

• Periprocedural and postprocedural safety events

  All cardiovascular adverse events or complications occurring during hospitalization and late complications after discharge related to EPS, ablation, or electrical cardioversion.

  Up to 24 months after procedure

• Clinical efficacy outcomes

  Procedural success, recurrence of arrhythmias or symptoms, and need for repeat EPS/cardioversion, additional medication, or device implantation (e.g., pacemaker).

  Up to 24 months after procedure

Secondary Outcomes (2)

• All-cause mortality

  Up to 24 months after procedure

• All-cause hospitalization

  Up to 24 months after procedure

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with heart rhythm disorders

You may qualify if:

• Patients who undergo an electrophysiological study (EPS) or electrical cardioversion at University Hospital Düsseldorf since 2015 (retrospective cohort)
• Patients scheduled to undergo an EPS or electrical cardioversion at University Hospital Düsseldorf from 2019 onward (prospective cohort) •- Written informed consent for participation in the registry (prospective part only)

You may not qualify if:

• \< 18 years
• Lack of written informed consent
• Pregnancy

Sponsors & Collaborators

• Heinrich-Heine University, Duesseldorf: lead

Study Sites (1)

University Hospital Duesseldorf

Düsseldorf, 40225, Germany

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Plasma

MeSH Terms

Conditions

Atrial Fibrillation; Atrial Flutter; Tachycardia, Supraventricular; Tachycardia, Ventricular

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Tachycardia; Cardiac Conduction System Disease

Study Officials

• Malte Kelm, MD

  Division of Cardiology, Pulmonary Disease and Vascular Medicine at University Hospital Duesseldorf

  STUDY CHAIR

• Obaida Rana, MD

  Division of Cardiology, Pulmonary Disease and Vascular Medicine at University Hospital Duesseldorf

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Obaida Rana, MD

CONTACT

+492118118800; obaida.rana@med.uni-duesseldorf.de

Lisa Dannenberg, MD

CONTACT

+ 49211 81 05315; LisaKristina.Dannenberg@med.uni-duesseldorf.de

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2025
• First Posted: September 29, 2025
• Study Start: June 1, 2019
• Primary Completion (Estimated): December 31, 2030
• Study Completion (Estimated): December 31, 2031
• Last Updated: September 29, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)